Spero Therapeutics (SPRO) Common Equity (2016 - 2026)

Spero Therapeutics (SPRO) has reported Common Equity for 11 consecutive years, with $44.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 34.65% year-over-year to $44.2 million; the trailing twelve-month figure through Jun 2026 stood at $44.2 million (up 34.65% YoY), and the FY2025 full-year result was $59.0 million, up 27.96% from the prior year.
• Common Equity retreated to $44.2 million in Q2 2026 per SPRO's latest filing, from $52.9 million in the prior quarter.
• Across five years, Common Equity topped out at $106.9 million in Q4 2023 and bottomed at $26.5 million in Q3 2025.
• Historically, Common Equity has averaged $56.9 million across 5 years, with a median of $54.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Common Equity tumbled 70.97% in 2022, then jumped 65.33% in 2023.
• Over 5 years, Common Equity stood at $75.9 million in 2022, then surged by 40.77% to $106.9 million in 2023, then sank by 56.85% to $46.1 million in 2024, then advanced by 27.96% to $59.0 million in 2025, then fell by 25.1% to $44.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $44.2 million, $52.9 million, and $59.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.